{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:04Z","timestamp":1793018104383,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Boehringer Ingelheim"],"award-info":[{"award-number":["Boehringer Ingelheim"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06297-9","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:56:56Z","timestamp":1790423816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Occurrence of progressive pulmonary fibrosis and its association with survival in connective tissue disease-associated interstitial lung disease: an international retrospective cohort study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1730","authenticated-orcid":false,"given":"Julien","family":"Guiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8896-6341","authenticated-orcid":false,"given":"Xavier M.","family":"Teitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-4014","authenticated-orcid":false,"given":"Jesper R\u00f8mhild","family":"Davidsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-1997","authenticated-orcid":false,"given":"Sanjeewa","family":"Patabendige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nibbering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Haaksma-Herczegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-2425","authenticated-orcid":false,"given":"Ana Catarina","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-2216","authenticated-orcid":false,"given":"Ana Rita Luis Alves","family":"Prata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-3497","authenticated-orcid":false,"given":"Wim A.","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"19","key":"6297_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM (2024) Interstitial Lung Disease: A Review. JAMA 331(19):1655\u20131665","journal-title":"JAMA"},{"key":"6297_CR2","doi-asserted-by":"publisher","first-page":"1296890","DOI":"10.3389\/fmed.2024.1296890","volume":"11","author":"MA Althobiani","year":"2024","unstructured":"Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR et al (2024) Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med (Lausanne) 11:1296890","journal-title":"Front Med (Lausanne)"},{"issue":"21","key":"6297_CR3","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.3390\/jcm10214830","volume":"10","author":"C Hyldgaard","year":"2021","unstructured":"Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T (2021) Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort. J Clin Med 10(21):4830","journal-title":"J Clin Med"},{"key":"6297_CR4","doi-asserted-by":"publisher","first-page":"1759720X2110375","DOI":"10.1177\/1759720X211037519","volume":"13","author":"P Panagopoulos","year":"2021","unstructured":"Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A (2021) Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 13:1759720X211037519","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 10","key":"6297_CR5","first-page":"Abstract254","volume":"71","author":"J Zhuo","year":"2019","unstructured":"Zhuo J, Bao Y, Xia Q, Rao A, Samal C, Lama S (2019) Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population. Arthritis Rheumatol 71(Suppl 10):Abstract254","journal-title":"Arthritis Rheumatol"},{"key":"6297_CR6","doi-asserted-by":"publisher","first-page":"102245","DOI":"10.1016\/j.coph.2022.102245","volume":"65","author":"TM Wilson","year":"2022","unstructured":"Wilson TM, Solomon JJ, Demoruelle MK (2022) Treatment approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pharmacol 65:102245","journal-title":"Curr Opin Pharmacol"},{"key":"6297_CR7","doi-asserted-by":"publisher","first-page":"684699","DOI":"10.3389\/fimmu.2021.684699","volume":"12","author":"T Shao","year":"2021","unstructured":"Shao T, Shi X, Yang S, Zhang W, Li X, Shu J et al (2021) Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Front Immunol 12:684699","journal-title":"Front Immunol"},{"issue":"1","key":"6297_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-017-0560-x","volume":"18","author":"GP Cosgrove","year":"2018","unstructured":"Cosgrove GP, Bianchi P, Danese S, Lederer DJ (2018) Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med 18(1):9","journal-title":"BMC Pulm Med"},{"issue":"8","key":"6297_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/acr.25348","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken) 76(8):1051\u20131069","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"25","key":"6297_CR10","first-page":"04320","volume":"S0003\u20134967","author":"KM Antoniou","year":"2025","unstructured":"Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N et al (2025) ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease. Ann Rheum Dis S0003\u20134967(25):04320\u201304321","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6297_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res 76(8):1070\u20131082","journal-title":"Arthritis Care Res"},{"key":"6297_CR12","doi-asserted-by":"crossref","unstructured":"Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N et al (2025) ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Respir J 2500896","DOI":"10.1016\/j.ard.2025.08.021"},{"issue":"2","key":"6297_CR13","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2(2):e71\u201383","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"6297_CR14","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1093\/rheumatology\/keaf200","volume":"64","author":"J Yang","year":"2025","unstructured":"Yang J, Head MA, Schott KD, Tan H, Djaraher R, Crowe CL et al (2025) Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis. Rheumatology (Oxford) 64(8):4713\u20134721","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"6297_CR15","doi-asserted-by":"publisher","first-page":"rkae056","DOI":"10.1093\/rap\/rkae056","volume":"8","author":"J Hannah","year":"2024","unstructured":"Hannah J, Rodziewicz M, Mehta P, Heenan KM, Ball E, Barratt S et al (2024) The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope. Rheumatol Adv Pract 8(2):rkae056","journal-title":"Rheumatol Adv Pract"},{"issue":"11","key":"6297_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1164\/rccm.201108-1420PP","volume":"185","author":"TJ Doyle","year":"2012","unstructured":"Doyle TJ, Hunninghake GM, Rosas IO (2012) Subclinical Interstitial Lung Disease. Am J Respir Crit Care Med 185(11):1147\u20131153","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"6297_CR17","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.3390\/jcm14176164","volume":"14","author":"JC Drimus","year":"2025","unstructured":"Drimus JC, Duma RC, Tr\u0103il\u0103 D, Mogo\u0219an CD, Manolescu DL, Fira-Mladinescu O (2025) High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis. J Clin Med 14(17):6164","journal-title":"J Clin Med"},{"issue":"3","key":"6297_CR18","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1378\/chest.12-0741","volume":"143","author":"R Vij","year":"2013","unstructured":"Vij R, Strek ME (2013) Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Chest 143(3):814\u2013824","journal-title":"Chest"},{"issue":"3","key":"6297_CR19","doi-asserted-by":"publisher","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","volume":"61","author":"SK Rajan","year":"2023","unstructured":"Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK et al (2023) Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J 61(3):2103187","journal-title":"Eur Respir J"},{"issue":"11","key":"6297_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD et al (2019) Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 35(11):2015\u20132024","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"6297_CR21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S2213-2600(21)00017-5","volume":"9","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N et al (2021) Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Med 9(9):1065\u20131076","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"6297_CR22","doi-asserted-by":"publisher","first-page":"e002368","DOI":"10.1136\/bmjresp-2024-002368","volume":"11","author":"L Fabbri","year":"2024","unstructured":"Fabbri L, Russell AM, Chaudhuri N, Adams W, Cowan K, Conway J et al (2024) Research priorities for progressive pulmonary fibrosis in the UK. BMJ Open Respir Res 11(1):e002368","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"6297_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","volume":"20","author":"V Liakouli","year":"2024","unstructured":"Liakouli V, Ciancio A, Del Galdo F, Giacomelli R, Ciccia F (2024) Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol 20(1):21\u201332","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"6297_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381(18):1718\u20131727","journal-title":"N Engl J Med"},{"issue":"9","key":"6297_CR25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al (2022) Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205(9):e18\u201347","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6297_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12931-024-03070-z","volume":"25","author":"AU Wells","year":"2024","unstructured":"Wells AU, Walsh SLF, Adegunsoye A, Cottin V, Danoff SK, Devaraj A et al (2024) Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study. Respir Res 25(1):448","journal-title":"Respir Res"},{"issue":"7","key":"6297_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","volume":"211","author":"AJ Podolanczuk","year":"2025","unstructured":"Podolanczuk AJ, Hunninghake GM, Wilson KC, Khor YH, Kheir F, Pang B et al (2025) Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement. Am J Respir Crit Care Med 211(7):1132\u20131155","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"6297_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5152\/TurkThoracJ.2022.21263","volume":"23","author":"H Wagih Abdelwahab","year":"2022","unstructured":"Wagih Abdelwahab H, Shalabi NM, Mohamed Rashad Ghoneim M, Saad Farrag N, Hamdy F, Elhoseiny F et al (2022) Screening for Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients: Functional and Radiological Methods. Turk Thorac J 23(4):261\u2013267","journal-title":"Turk Thorac J"},{"key":"6297_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70026","author":"M Hong","year":"2025","unstructured":"Hong M, Veitch E, Limaye S (2025) Connective tissue disease-associated interstitial lung disease: an approach to treatment amidst an expanding evidence base. Intern Med J. https:\/\/doi.org\/10.1111\/imj.70026","journal-title":"Intern Med J"},{"issue":"9","key":"6297_CR30","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1093\/rheumatology\/kead027","volume":"62","author":"SH Chang","year":"2023","unstructured":"Chang SH, Lee JS, Ha YJ, Kim MU, Park CH, Lee JS et al (2023) Lung function trajectory of rheumatoid arthritis\u2013associated interstitial lung disease. Rheumatology (Oxford) 62(9):3014\u20133024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6297_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","volume":"19","author":"C Chan","year":"2019","unstructured":"Chan C, Ryerson CJ, Dunne JV, Wilcox PG (2019) Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med 19(1):192","journal-title":"BMC Pulm Med"},{"issue":"7","key":"6297_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/17476348.2022.2107508","volume":"16","author":"M Molina-Molina","year":"2022","unstructured":"Molina-Molina M, Castellv\u00ed I, Valenzuela C, Ramirez J, Rodr\u00edguez Portal JA, Franquet T et al (2022) Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 16(7):765\u2013774","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"6297_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s41030-025-00302-5","volume":"11","author":"IE Montero","year":"2025","unstructured":"Montero IE, Hernandez-Gonzalez F, Sellares J (2025) Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review. Pulm Ther 11(3):347\u2013363","journal-title":"Pulm Ther"},{"issue":"4","key":"6297_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.resinv.2024.05.005","volume":"62","author":"Y Kondoh","year":"2024","unstructured":"Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W (2024) Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database. Respiratory Invest 62(4):702\u2013709","journal-title":"Respiratory Invest"},{"issue":"22","key":"6297_CR35","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M et al (2025) Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med 392(22):2203\u20132214","journal-title":"N Engl J Med"},{"issue":"1","key":"6297_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","volume":"22","author":"M Nasser","year":"2021","unstructured":"Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S et al (2021) Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res 22(1):162","journal-title":"Respir Res"},{"issue":"3","key":"6297_CR37","doi-asserted-by":"publisher","first-page":"00926","DOI":"10.1183\/23120541.00926-2024","volume":"11","author":"J Behr","year":"2025","unstructured":"Behr J, Kreuter M, Guenther AU, Bonella F, Pittrow D, Pausch C et al (2025) Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry. ERJ Open Res 11(3):00926\u20132024","journal-title":"ERJ Open Res"},{"issue":"Suppl 55","key":"6297_CR38","doi-asserted-by":"publisher","first-page":"P656","DOI":"10.1183\/13993003\/erj.38.Suppl_55.p656","volume":"38","author":"FS Pires","year":"2011","unstructured":"Pires FS, Damas C, Mota P, Melo N, Costa D, Jesus JM et al (2011) Slow versus rapid progressors in idiopathic pulmonary fibrosis. Eur Respir J 38(Suppl 55):P656","journal-title":"Eur Respir J"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06297-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06297-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:21Z","timestamp":1793016201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06297-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6297"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06297-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JG reports personal fees for advisory board, work, and lectures from Boehringer Ingelheim, Janssen, SMB, GSK, Pfizer, Daichii-Sankyo, Roche, AstraZeneca, Aquilon, Voliyion, Oncoradiomics, and Chiesi, non-financial support for meeting attendance from AstraZeneca, Chiesi, MSD, Roche, Boehringer Ingelheim, and Janssen. XMT, KN, and MHH are employees of Boehringer Ingelheim B.V. TD has received fees for lectures and participating in advisory board meetings outside this study from Abbvie, Amgen, Boehringer Ingelheim, Elpen, Genesis Pharma, GlaxoSmithKline, Johnson-Johnson, MSD, Lilly, Pfizer, Sobi and UCB. JRD has received outside this study fees for teaching lectures, advisory board consultancy honoraria, and travel grants from Boehringer Ingelheim and advisory board consultancy honoraria from AstraZeneca. SP has received outside this study speaker fees from Boehringer Ingelheim. LS is an employee of TFS HealthScience, ACD has received fees for lectures and participating in advisory board meetings outside this study from Boehringer Ingelheim. ARLAP has declared no conflict of interest. WAW reports grants and fees from Boehringer Ingelheim, Hoffman la Roche, Galapagos and Sanofi, outside the submitted work, paid to his institution.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"266"}}